To explore the prognostic significance of concurrent TP53/RB1 alterations, we investigated the correlation between four genotypic subgroups (based on TP53 and RB1 mutation status) and the prognosis of patients across a pan‐cancer cohort. The gene discussed is TP53; the disease is cancer.